Join Growin Stock Community!

Medicus pharma ltd.MDCXW.US Overview

US StockHealthcare
(No presentation for MDCXW)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

MDCXW AI Insights

MDCXW Overall Performance

MDCXW AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MDCXW Recent Performance

-18.73%

Medicus pharma ltd.

0.05%

Avg of Sector

-0.31%

S&P500

MDCXW PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

MDCXW Key Information

MDCXW Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

MDCXW Profile

Medicus Pharma Ltd. is a clinical-stage biotech company focused on accelerating the development of novel therapeutic assets. Their lead subsidiary, SkinJect Inc., is developing a non-invasive treatment for basal cell carcinoma using a dissolvable microneedle patch to deliver chemotherapeutic agents directly to tumor cells.

Price of MDCXW

MDCXW FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MDCXW Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.34
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.34
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is MDCXW's latest earnings report released?

    The most recent financial report for Medicus pharma ltd. (MDCXW) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MDCXW's short-term business performance and financial health. For the latest updates on MDCXW's earnings releases, visit this page regularly.

  • How much debt does MDCXW have?

    As of the end of the reporting period, Medicus pharma ltd. (MDCXW) had total debt of 236.26K, with a debt ratio of 0.42. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does MDCXW have?

    At the end of the period, Medicus pharma ltd. (MDCXW) held Total Cash and Cash Equivalents of 8.66M, accounting for 0.87 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is MDCXW's EPS continuing to grow?

    According to the past four quarterly reports, Medicus pharma ltd. (MDCXW)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.12. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of MDCXW?

    Medicus pharma ltd. (MDCXW)'s Free Cash Flow (FCF) for the period is -6.83M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 122.64% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of MDCXW?

    The latest valuation data shows Medicus pharma ltd. (MDCXW) has a Price-To-Earnings (PE) ratio of -0.51 and a Price/Earnings-To-Growth (PEG) ratio of -0.21. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.